BDRX (Biodexa Pharmaceuticals) Other Current Payables: $0.02 Mil (As of Dec. 2025)


BDRX Biodexa Pharmaceuticals PLC BDRX
45 GF Score
Price $2.69
GF Value $2.33
View Full Analysis

What is Biodexa Pharmaceuticals Other Current Payables?

Biodexa Pharmaceuticals BDRX -6.62% 45 Other Current Payables is $0.02 Mil as of Dec. 2025. GuruFocus rates BDRX with a GF Score™ of 45/100 and a GF Value™ of $2.33.

Biodexa Pharmaceuticals's Other Current Payables for the quarter that ended in Dec. 2025 was $0.02 Mil.

Biodexa Pharmaceuticals's quarterly Other Current Payables declined from Dec. 2024 ($0.01 Mil) to Jun. 2025 ($0.00 Mil) but then increased from Jun. 2025 ($0.00 Mil) to Dec. 2025 ($0.02 Mil).

Biodexa Pharmaceuticals's annual Other Current Payables declined from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.01 Mil) but then increased from Dec. 2024 ($0.01 Mil) to Dec. 2025 ($0.02 Mil).

Biodexa Pharmaceuticals Other Current Payables Related Terms

Biodexa Pharmaceuticals Other Current Payables Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals Other Current Payables Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.02 0.01 0.01 0.02

Biodexa Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.01 0.00 0.02
BDRX
45GF Score
Biodexa Pharmaceuticals PLC BDRX
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodexa Pharmaceuticals Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.02 Mil mean?
Biodexa Pharmaceuticals (BDRX) has a Other Current Payables of $0.02 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Biodexa Pharmaceuticals and its competitors.
Is Biodexa Pharmaceuticals' Other Current Payables too high?
Biodexa Pharmaceuticals' current Other Current Payables is $0.02 Mil. Overall, Biodexa Pharmaceuticals has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Other Current Payables compare to ADTX and AAGH?
Biodexa Pharmaceuticals' Other Current Payables of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current Other Current Payables is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (BDRX) has a current Other Current Payables of $0.02 Mil. The stock's GF Value™ is $2.33, compared to a current price of $2.69 — trading 15.5% above its estimated fair value. The current Other Current Payables is $0.02 Mil. Biodexa Pharmaceuticals' overall GF Score™ is 45/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Biodexa Pharmaceuticals (BDRX), the current Other Current Payables is $0.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (BDRX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of $2.69 is trading 15.5% above its estimated GF Value™ of $2.33.

Key valuation signals for BDRX:

  • Other Current Payables: $0.02 Mil
  • GF Value™: $2.33 vs. price of $2.69 (15.5% above fair value)
  • GF Score™: 45/100

No single metric tells the full story. See the BDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
45GF Score

Get the complete analysis for BDRX

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.69
Price
$2.33
GF Value